TY - JOUR
T1 - Topical delivery of meropenem via spanlastic carbopol gel
T2 - in-vitro studies and in-vivo application in pressure ulcers
AU - Abdelfattah, Shadwa
AU - Mady, Fatma Mohamed
AU - Sarhan, Hatem A.
AU - Khalifa, Hazim O.
AU - Hashem, Hamada
AU - Hassan, Hesham
AU - Alkhammash, Abdullah
AU - Hadiya, Safy
AU - Ibrahem, Reham Ali
AU - Qelliny, Milad Reda
N1 - Publisher Copyright:
Copyright © 2025 Abdelfattah, Mady, Sarhan, Khalifa, Hashem, Hassan, Alkhammash, Hadiya, Ibrahem and Qelliny.
PY - 2025
Y1 - 2025
N2 - Introduction: Spanlastics, a type of elastic nanovesicle, represents a promising drug delivery system capable of encapsulating both hydrophilic and lipophilic drug compounds. These carriers are biodegradable, biocompatible, and non-immunogenic. Meropenem (MRP), a broad-spectrum carbapenem antibiotic, is widely used to treat severe infections in both adults and children before the causative pathogens are identified. However, meropenem’s aqueous formulations are highly unstable and must be administered within 24 h of preparation. This study aimed to develop a meropenem-loaded spanlastic formulation (MRP-SP) for topical application, aiming to enhance both the drug’s stability and skin permeability. Methods: Spanlastics were prepared using Span 60 and Brij 35 via the ethanol injection method. The MRP-SP formulation was extensively characterized through particle size analysis, polydispersity index (PDI), zeta potential, encapsulation efficiency, in vitro drug release, scanning electron microscopy, microbiological assays, and in vivo topical efficacy studies. Results and Discussion: The optimized formulation (Batch F5), composed of Span 60 and Brij 35 in a 1:4 M ratio, exhibited a particle size of 462 nm, spherical morphology, 69.5% drug encapsulation efficiency, and 20% drug release within 6 h. The gel form of the same batch showed a comparable release profile. Antibacterial testing revealed that MRP-SP reduced the minimum inhibitory concentration by 2.4-fold against Pseudomonas aeruginosa compared to free MRP. Additionally, MRP-SP significantly downregulated the expression of mexA, a key resistance gene. In vivo, the topical application of MRP-SP demonstrated superior therapeutic activity in treating ulcerative skin lesions in non-diabetic mice, as evidenced by wound closure percent (89% at 10 days), wound area (49% at 10 days), and histopathological improvements. Overall, the meropenem-loaded spanlastic formulation shows strong potential as an effective topical therapy for bacterial skin infections.
AB - Introduction: Spanlastics, a type of elastic nanovesicle, represents a promising drug delivery system capable of encapsulating both hydrophilic and lipophilic drug compounds. These carriers are biodegradable, biocompatible, and non-immunogenic. Meropenem (MRP), a broad-spectrum carbapenem antibiotic, is widely used to treat severe infections in both adults and children before the causative pathogens are identified. However, meropenem’s aqueous formulations are highly unstable and must be administered within 24 h of preparation. This study aimed to develop a meropenem-loaded spanlastic formulation (MRP-SP) for topical application, aiming to enhance both the drug’s stability and skin permeability. Methods: Spanlastics were prepared using Span 60 and Brij 35 via the ethanol injection method. The MRP-SP formulation was extensively characterized through particle size analysis, polydispersity index (PDI), zeta potential, encapsulation efficiency, in vitro drug release, scanning electron microscopy, microbiological assays, and in vivo topical efficacy studies. Results and Discussion: The optimized formulation (Batch F5), composed of Span 60 and Brij 35 in a 1:4 M ratio, exhibited a particle size of 462 nm, spherical morphology, 69.5% drug encapsulation efficiency, and 20% drug release within 6 h. The gel form of the same batch showed a comparable release profile. Antibacterial testing revealed that MRP-SP reduced the minimum inhibitory concentration by 2.4-fold against Pseudomonas aeruginosa compared to free MRP. Additionally, MRP-SP significantly downregulated the expression of mexA, a key resistance gene. In vivo, the topical application of MRP-SP demonstrated superior therapeutic activity in treating ulcerative skin lesions in non-diabetic mice, as evidenced by wound closure percent (89% at 10 days), wound area (49% at 10 days), and histopathological improvements. Overall, the meropenem-loaded spanlastic formulation shows strong potential as an effective topical therapy for bacterial skin infections.
KW - edge activator
KW - meropenem
KW - mexA expression
KW - pressure ulcers
KW - spanlastics
KW - transdermal
UR - https://www.scopus.com/pages/publications/105018681892
UR - https://www.scopus.com/pages/publications/105018681892#tab=citedBy
U2 - 10.3389/fphar.2025.1672677
DO - 10.3389/fphar.2025.1672677
M3 - Article
AN - SCOPUS:105018681892
SN - 1663-9812
VL - 16
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1672677
ER -